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hormoneAbstract Aims: Rheumatic valve diseases are most common etiological valve diseases in develop-
ing countries. Urotensin II is cardiovascular autacoid/hormone and may be associated with patients
of heart valve diseases. The present study was to measure plasma urotensin II concentrations in
patients with left-sided rheumatic valve diseases such as mitral regurgitation (MR) and aortic regur-
gitation (AR), and to examine its correlation with severity of valve impairment, function (New
York Heart association, NYHA) class and pulmonary artery pressure (PAP).
Methods and results: Sixty patients with moderate to severe rheumatic left-sided valve regurgitation
and 20 healthy controls were selected after performing the echocardiography. Plasma urotensin II
level was measured in all subjects. The patients with MR and AR were significantly increased of left
ventricular end diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left
atrial diameter, PAP, but decreased of EF% versus the controls. Urotensin II level was highly sig-
nificant in patients with MR (1.83 ± 0.92 ng/ml, P< 0.001) and AR (0.79 ± 0.3 ng/ml, P< 0.05)
versus the controls (0.48 ± 0.13 ng/ml). Also, there was significant correlation between Urotensin II
level and LVEDD (MR, r= 0.318, P= 0.03; AR, r= 0.805, P< 0.001), LVESD (MR,
r= 0.271, P= 0.115; AR, r= 0.614, P= 0.001), and PAP (MR, r= 0.706, P< 0.001; AR,
r= 0.129, P= 0.538).
Conclusion: Urotensin II was elevated in patients with rheumatic left-sided valvular regurgitation,
and positively correlated with increased LVEDD (in both MR and AR), LVESD (only AR) and
pulmonary artery pressure (only MR). Therefore, urotensin II level may be used as diagnostic bio-
marker in patients with rheumatic valvular diseases for assessment of the severity in parallel with
echocardiography.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(2016),
2 I. Elmadbouh et al.1. Introduction
Human urotensin II is an 11 amino acid cyclic peptide and is
expressed in most tissue organs of body including the heart
and blood vessels, suggesting that urotensin II has a role in
cardiovascular diseases1. Human urotensin II is the most
potent vasoconstrictor, and more potent than endothelin-1
and acts through a G-protein-coupled receptor.1,2 Urotensin
II and urotensin II receptor are up-regulated in a number of
cardiovascular disease states, implicating the urotensin II sys-
tem in the pathogenesis and progression of cardiovascular
diseases.3
Urotensin II has pleiotropic effects within the cardiovascu-
lar system, with evidence for modulation of cardiac contractil-
ity, vascular tone, cell proliferation, and cell growth. Recent
studies have suggested that urotensin II may have a protective
effect on the cardiovascular system, while others implicate uro-
tensin II as a harmful mediator.4 Evidence suggests that the
condition of the vascular endothelium is a key determinant
in how the cardiovascular system responds to urotensin II.1,4
In the developing countries of the world, rheumatic fever
and rheumatic valve disease (RVD) remain among significant
medical and public health problems.5–7 Considerable numbers
of young adults are in need of valve surgery. The primary con-
sideration in management of adults with valvular heart disease
is symptom status, emphasizing the importance of the clinical
history. Besides assessment of valve anatomy, careful monitor-
ing of symptoms due to chronic rheumatic valve disease is
important during follow-up.6
Furthermore, echocardiographic screening of asymp-
tomatic patients who have severe rheumatic valve disease
remains the best tool for risk stratification and surgical indica-
tion. Attentive echocardiographic evaluation for objective
signs of severity and complications of valve disease is recom-
mended for patients with doubtful symptoms.7,8
Recently, the chronic phase of RVD is associated with
ongoing plasma inflammatory mediators (e.g. atrial and brain
natriuretic peptides) which correlate strongly with the severity
of valve involvement, valve scarring, subsequent valve calcifi-
cation and decreasing NYHA class.8
Many studies have been performed on the cardiovascular
relation of urotensin II and documented elevated plasma uro-
tensin II level in congestive heart failure,9–11 coronary artery
disease2,3,12 and hypertension.1 However plasma urotensin II
level in subjects with the rheumatic valve disease is not yet
clear.13 Urotensin II is mainly regarded as a cardiovascular
autacoid/hormone; it might have a pathophysiological role in
rheumatic valve disease.
The present study was to measure plasma urotensin II con-
centrations in patients with rheumatic mitral or aortic regurgi-
tation and to examine its correlation with severity of valve
impairment, function (NYHA) class and pulmonary artery
pressure.
2. Subjects and methods
2.1. Subjects
This study was performed in patient at cardiology department
of Menoufia University Hospital and Police Academy Hospi-Please cite this article in press as: Elmadbouh I et al. The value of urotensin II in pat
http://dx.doi.org/10.1016/j.ehj.2016.09.006tal and Nasser Institute Hospital, Cairo, Egypt, from March
2011 to December 2015.
A written informed consent, full history taking, and com-
plete general and local examination of the heart, chest and
abdomen, electrocardiography (ECG), full echo-doppler study
and blood sample for plasma urotensin-II concentration were
performed for all subjects.
The patients with isolated rheumatic mitral (n= 35) and
aortic (n= 25) valve regurgitation and another healthy con-
trols (n= 20) after performing echocardiography were
selected in this study.
Exclusion criteria: Any concomitant valve lesion other than
mitral and aortic valves, more than mild mitral stenosis,
ischemic heart disease, severe systolic heart failure and any
other congenital heart disease.
2.2. Methods
2.2.1. Echocardiographic study
Full M-mode, 2-D and Doppler echocardiographic study was
done to all patients included in the study using GE vivid III
echocardiography machine; 4-chamber, 5-chamber and 2
chamber apical views were obtained. Parasternal long and
short axis views were also obtained.
2.2.2. Plasma urotensin-II measurement
Blood samples were collected into tubes containing EDTA and
aprotinin (0.6 TIU/mL of blood). Then, plasma was stored at
70 C until the day of the assay. Human plasma Urotensin II
was measured by an enzyme-linked immunoassay (EIA)
method. A specific and sensitive EIA kit was used for this
assay (Phoenix Pharmaceutical Inc., California, USA).
2.3. Statistical analysis
Data of all patients were collected and analyzed using statisti-
cal package SPSS for PC version 16.5. Descriptive statistics
were done using mean and standard deviation for continuous
variables and percentage for categorical variables. Non-
paired Student’s t-test was done to find out the presence of sig-
nificant difference between groups in continuous variables.
Chi-square test was done to find out the presence of significant
difference between groups in categorical variables. Pearson
correlation coefficient was done to find out the presence of sig-
nificant correlation between urotensin II and the different
parameters. The P value< 0.5 was considered significant.
3. Results
3.1. Patients’ demographic data
This study was performed on 35 patients with rheumatic mitral
regurgitation and 25 patients with rheumatic aortic regurgita-
tion and another 20 ages and sex matched healthy control
group. The mean age of MR patients was 42 ± 4.2 years, 15
males (42.8%) and 20 females (57.2%). 20 patients (57.1%)
had atrial fibrillation (AF), no one was in NYHA class I or
IV but 18 patients (51.4%) had NYHA class II and 17 patients
(48.6%) had NYHA class III. The mean age of the AR
patients was 42.44 ± 3.1 years, 12 males (48%) and 13 femalesients with left-sided rheumatic valvular regurgitation, The Egypt Heart J (2016),
Table 1 General and demographic characteristics of all subjects.
Mitral regurgitation Aortic regurgitation Healthy controls P value
n= 35 n= 25 n= 20
Age (mean ± SD) 42.06 ± 4.2 42.44 ± 3.1 42.45 ± 3.3 >0.05a
>0.05b
Sex
Males 15 (42.8%) 12 (48%) 9 (45%) >0.05a
Females 20 (57.2%) 13 (52%) 11 (55%) >0.05b
Sinus rhythm 15 (42.9%) 24 (96%) 20 (100%)
Atrial fibrillation (AF) 20 (57.1%) 1 (4%) 0 NA
NYHA class
I 0 0 0 NA
II 18 (51.4%) 2 (8%) 0 NA
III 17 (48.6%) 10 (40%) 0 NA
IV 0 13 (52%) 0 NA
NA: Not Applicable.
a Mitral regurgitation versus normal patients.
b Aortic regurgitation versus normal patients.
Urotensin II and valvular regurgitation 3(52%). Only 1 patient (4%) had atrial fibrillation (AF), no one
was in NYHA class I or IV but in 11 patients,44% had NYHA
class II and 14 patients (56%) had NYHA class III. In the
healthy control group, their mean age was 42.4 ± 3.3 years,
9 males (45%) and 11 females (55%). All patients of this group
were in sinus rhythm and they were apparently healthy individ-
uals. There was no significant difference between the MR or
AR and control groups regarding their mean age or their sex
distribution (P> 0.05) (Table 1).
3.2. The echocardiographic study in all subjects
The left atrial dimension (LA), left ventricular end diastolic
diameter (LVEDD) and left ventricular end systolic diameter
(LVESD) and the pulmonary artery pressure (PAP), were sig-
nificantly higher among MR or AR patient groups than those
of the healthy controls (P< 0.001). Ejection fraction was sig-
nificantly lower among the patients groups than that of the
healthy controls (P< 0.001) (Table 2).
3.3. Plasma Urotensin II in all subjects
The mean Urotensin-II level was among the MR patients
(1.83 ± 0.92 ng/ml, P< 0.001) and AR patients (0.79
± 0.3 ng/ml, P< 0.05) versus 0.48 ± 0.13 ng/ml for the con-
trols (Table 3).
3.4. Assessment Urotensin II in valve regurgitation
There was significant positive correlation of urotensin-II level
with LVEDD (r= 0.318, P= 0.03) and PAP (r= 0.706,
P< 0.001) in MR patients, but, there was no significant cor-
relation with LVESD (r= 0.271, P= 0.115) (Table 4,
Fig. 1). In AR patients, there was significant positive correla-
tion of urotensin-II level with LVEDD (r= 0.805,
P< 0.001) and LVESD (r= 0.614, P= 0.001). There was
no significant correlation between urotensin level and the clin-
ical or other echocardiographic parameters (Table 4, Fig. 1).Please cite this article in press as: Elmadbouh I et al. The value of urotensin II in pat
http://dx.doi.org/10.1016/j.ehj.2016.09.0064. Discussion
Human urotensin II has several cardiovascular actions, includ-
ing potent vasoactive, and cardiac inotropic and hypertropic
properties.14 Altered plasma concentrations of urotensin II in
diseases, such as heart failure, essential hypertension, renal dis-
ease, diabetes, and liver cirrhosis12,15 have raised the notion
that urotensin II may be a useful biomarker in detecting dis-
ease onset or progression.16
The present study was conducted on patients with rheu-
matic mitral or aortic regurgitation versus healthy controls
for clinical examination and echocardiographic assessment.
Our results were in agreement with the study by Ozer et al.13
who studied 71 patients with RVD (mean age 40 ± 12 years,
17 female patients) and 25 normal subjects (mean age 40
± 7 years, 8 female patients). They assessed their New York
Heart Association (NYHA) functional class, RVD severity
and pulmonary artery pressure (PAP), and measured plasma
urotensin II levels. They found that urotensin II level was sig-
nificantly higher in patients with rheumatic heart disease.
The present study showed that there was significant positive
correlation between urotensin-II level, PAP, and LVEDD.
These results were in agreement with the study by Ozer et al.13
who found that urotensin II was significantly correlated with
mitral regurgitation (r= 0.226, P= 0.02), PAP (r= 0.320,
P= 0.01), and NYHA class (r= 0.213, P= 0.03). There
was positive correlation between urotensin II levels and sever-
ity of mitral regurgitation (r= 0.248, P= 0.01). In linear
regression analysis, only PAP was predictive of urotensin II
(r= 0.3; P= 0.02). They concluded that plasma urotensin
II is elevated in chronic RVD, associated with severe mitral
and tricuspid valve regurgitation. Furthermore, urotensin II
level is correlated with NYHA functional class, and the
increase in PAP is predictive of plasma urotensin II.
The LVEDD was found to be a predictive of urotensin II
level in this study and these results were not in agreement with
the results of Ozer et al.13 and this difference may be due that
our patients had a more dilated LV dimensions and more
impaired LV systolic function.ients with left-sided rheumatic valvular regurgitation, The Egypt Heart J (2016),
Table 2 Echocardiographic assessment in all subjects.
Mitral regurgitation Aortic regurgitation Healthy controls P value
n= 35 n= 25 n= 20
LA (cm) 4.7 ± 0.6 3.4 ± 0.4 2.9 ± 0.2 <0.001a
<0.05b
LVEDD (cm) 5.95 ± 0.5 6.1 ± 0.4 4.9 ± 0.35 <0.001a
<0.001b
LVESD (cm) 3.94 ± 0.33 4.0 ± 0.34 3.0 ± 0.18 <0.001a
<0.001b
EF (%) 57.83 ± 3.0 55.4 ± 3.1 64.8 ± 3.1 <0.001a
<0.001b
PAP (mmHg) 45.0 ± 7.7 28.1 ± 5.6 23.9 ± 2.9 <0.001a
<0.05b
PAP: pulmonary artery pressure, LA: left atrium, LVED: left ventricular end-diastolic diameter, LVESD: left ventricular end-systolic diameter,
EF: Ejection fraction.
a Mitral regurgitation versus normal patients.
b Aortic regurgitation versus normal patients.
Table 3 Plasma urotensin-II levels in all subjects.
Mitral regurgitation Aortic regurgitation Healthy controls P value
n= 35 n= 25 n= 20
Plasma Urotensin-II (ng/ml) 1.83 ± 0.92 0.79 ± 0.3 0.48 ± 0.13 <0.001a
<0.05b
a Mitral regurgitation versus normal patients.
b Aortic regurgitation versus normal patients.
Table 4 Pearson correlation was measured between urotensin-II level and the different studied parameters among patients with mitral
and aortic regurgitations.
Mitral regurgitation Aortic regurgitation
n= 35 n= 25
r P value r P value
Age 0.039 0.826 0.309 0.132
NYHA 0.199 0.251 0.253 0.223
AF 0.042 0.812 0.117 0.578
LA 0.001 0.997 0.066 0.755
LVEDD 0.318 0.03** 0.805 0.0001**
LVESD 0.271 0.115 0.614 0.001**
EF 0.015 0.931 0.105 0.618
PAP 0.706 0.0001** 0.129 0.538
AR 0.160 0.358
MR 0.155 0.461
AF: Atrial fibrillation, PAP: pulmonary artery pressure, LA: left atrium, LVED: left ventricular end-diastolic diameter, LVESD: left ventricular
end-systolic diameter, EF: Ejection fraction, MR: Mitral regurgitation, AR: Aortic regurgitation.
** P value is significant.
4 I. Elmadbouh et al.Our results were in agreement with the study17,18 that
showed the expression of myocardial urotensin II in patients
with heart failure. They found strong expression of urotensin
II in the cardiomyocytes, and to a lesser extent in the vascular
smooth muscle cells of patients with CHF. They also found
that myocardial expression of urotensin II correlated signifi-
cantly with LVEDD (P= 0.0092) and inversely with ejectionPlease cite this article in press as: Elmadbouh I et al. The value of urotensin II in pat
http://dx.doi.org/10.1016/j.ehj.2016.09.006fraction (P= 0.0002). They suggested a possible role for uro-
tensin II in the cardiac dysfunction and remodeling character-
istic of CHF.
Also Quaile et al.17 found that urotensin-II was an endoge-
nous peptide upregulated in failing hearts. To date, insights
into the myocardial actions of urotensin II have been obscured
by its potent vasoconstrictor effects and interspecies differ-ients with left-sided rheumatic valvular regurgitation, The Egypt Heart J (2016),
Figure 1 Linear regression analysis of the multiple echocardiographic factors that predict elevated urotensin II level in mitral
regurgitation (MR) (A, B) and aortic regurgitation (AR) (C, D) with left ventricular end diastolic dimension (LVEDD) (A, C) and
pulmonary artery pressure (PAP) (B, D).
Urotensin II and valvular regurgitation 5ences in physiological responses to urotensin II. They exam-
ined the direct effects of exogenous urotensin II on in vitro
contractility in nonfailing and failing human myocardial tra-
beculae. They found that urotensin II modulates contractility
independent of vasoconstriction with opposite effects in failing
and nonfailing hearts. Positive inotropic responses to uroten-
sin II alone suggest that increased endogenous urotensin II
constrains contractility in failing hearts via an autocrine and/
or paracrine mechanism.18 These findings support a potential
therapeutic role for urotensin II in heart failure.
Our results showed that pulmonary hypertension was a
strong predictor of urotensin II level and this could be
explained by that urotensin II was quickly revealed to be a very
potent vasoconstrictor. The action of urotensin II was found
to be independent of endothelial cells and to work via mobi-
lization of intracellular calcium as well as through stimulation
of extracellular calcium influx.19
As aforementioned, the actions of urotensin II in the pul-
monary circulation are quite variable.19 These variations at
different levels of the pulmonary circulation make it difficult
to understand the role of urotensin II in pulmonary
hypertension.Please cite this article in press as: Elmadbouh I et al. The value of urotensin II in pat
http://dx.doi.org/10.1016/j.ehj.2016.09.0064.1. Conclusion
The present study indicates that urotensin II level may have a
diagnostic of severe rheumatic valve regurgitation and can be
used to follow up as a prognostic role in the pathophysiology
of rheumatic heart disease and myocardial damage associated
with valvular affection. This study consisted of relatively small
number of patients. So it is recommended to have further stud-
ies with larger groups of patients to assess the relation between
urotensin II and severity of all valvular lesions.
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